BioMarin Pharmaceutical Inc. (BMRN)
| Previous close | 70.55 |
| Open | 70.86 |
| Bid | 69.75 x 100 |
| Ask | 74.69 x 100 |
| Day's range | 70.12 - 71.58 |
| 52-week range | 68.83 - 99.56 |
| Volume | |
| Avg. volume | 2,212,327 |
| Market cap | 13.522B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 53.81 |
| EPS (TTM) | 1.32 |
| Earnings date | 30 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 103.45 |
PR NewswireBioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that positive data from the CANOPY clinical program evaluating VOXZOGO® (vosoritide) in children with achondroplasia and other genetic skeletal conditions will be presented at the 16th International Skeletal Dysplasia Society meeting (ISDS) in Madrid, Sept. 18-21, 2024. These results include data showing that children with achondroplasia treated with VOXZOGO experienced meaningful improvements beyond height, such as in health-related qu
ZacksAscendis Soars on Encouraging Data From Dwarfism Drug Study
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
Investor's Business DailyAscendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.
